The nuclear phosphoprotein p53 was first identified on coprecipitation with SV40 large T antigen from SV40 infected murine cells (Lane & Crawford, 1979; Linzer & Levine, 1979) , the first observed interaction between a host cell protein and a viral oncogene (Lane & Benchimol, 1990) . Normal p53 is found at low levels in virtually all mammalian cells (Rogel et al., 1985) and various studies have shown elevated levels of the mRNA and protein in a wide variety of tumours and tumour cell lines (Linzer & Levine, 1979; De Leo et al., 1979; Crawford et al., 1981; Benchimol et al., 1982; Rotter, 1983; Thomas et al., 1983) including breast cancer (Cattoretti et al., 1988; Thompson et al., 1990) . The normal function of p53 is not known, but it is thought to be involved in the GO/GI to S transition in the cell cycle (Mercer et al., 1984; Ganon & Lane, 1987) where regulation of its activity may be through phosphorylation. Evidence suggests that p53 may behave as a negative regulator, that it is essential for normal growth and that its inactivation may be necessary for the development of malignancy (Lane & Benchimol, 1990) . p53 was initially thought to behave like an oncogene in that it transformed normal rat fibroblasts when co-transfected with activated Ha-ras (Eliyahu et al., 1984; Jenkins et al., 1984; Parada et al., 1984) . Subsequently this was shown to be true only for mutant p53 and not for the normal product of the wild-type allele (Eliyahu et al., 1988; . In fact, the normal allele, when co-transfected with activated ras plus mutant p53, behaves as a tumour suppressor . Tumour suppressor genes behave in a recessive way so that inactivation or loss of both alleles is required for tumour progression to occur (Knudson, 1971; Stanbridge, 1976) . Loss of heterozygosity (LOH) studies have implicated a number of chromosomal sites consistently lost in the development of particular tumours (Ponder, 1988) . Hemizygosity for chromosome 17pl3.1, a region in which the human p53 gene is located (Isobe et al., 1986) , was shown to occur in a high proportion of colorectal carcinomas (Vogelstein et al., 1989) and, based on the hypothesis that p53 might behave as a tumour suppressor gene, mutations were looked for and found in the remaining allele of two such patients . Subsequently mutations in p53 have been found in a number of tumours or tumour cell lines where LOH for 17p has been reported , including a recent study by our own group on sporadic breast tumours (Prosser et al., 1990) . In our own studies, in which our search for mutations was restricted to part of the p53 gene, we found that eight out of 60 tumours contained a mutation in exons five or six and estimated that these findings reflected the presence of a p53 mutation in some 30% of all sporadic breast tumours.
More than 60% of breast cancer patients show LOH for markers in the 17p region (Mackay et al., 1988; Devilee et al., 1989; Thompson et al., 1990 (Figure 2 ) and all segments were tested by hydroxylamine and osmium tetroxide modification, followed by piperidine cleavage (Figure 3 ). Using the oligos listed in Figure 2 we would expected to find mutations in the p53 exons and in the splice junctions of the introns (with the exception of the splice junction 5' to exon 2 and the first five nucleotides of that exon). As long as the gene is correctly spliced, it is possible that intron mutations could be tolerated, but to date there is no evidence about this with regard to the p53 gene. In the literature, mutations in p53 associated with particular tumours have been reported exclusively in exons Prosser et al., 1990 and references therein). In the ten individuals included in this study no mutations were found in the p53 genes as covered by the oligos used. We conclude that in these five families structural abnormalities of the p53 gene do not contribute to the inherited propensity to develop breast cancer. It should also be noted that none of the eight breast cancer patients in whose tumours we had detected p53 mutations gave a positive family history of the disease (Prosser et al., 1990) . Evidence from this laboratory (Coles et al. 1990 ) implicates two independent regions of LOH on chromosome 17p in breast tumours; one encompasses the p53 gene, but the more common one is some 20 megabases telomeric to it. It remains possible, therefore, that a mutation in another tumour suppressor gene on 17p is involved in heritable breast tumours. , segment III using osmium tetroxide (OS04). The positive control ( x 2) in a is a tumour mutation in p53 segments III (32T). The positive control in b is and al antitrypsin mutation in which the two heteroduplexes contain respectively a C and a T mismatch and both are visible. The negative control is (l antitrypsin homoduplex. The technique for HA modification is as described in Prosser et al. (1990) . For OS04 modification, essentially the same procedure was followed except that the heteroduplex was taken up in 61t ITE, 2.5 tlI of 10 x buffer (100mM Tris pH 7.7, 10mM EDTA, 15% pyridine) was added and 15 fLI of freshly diluted OS04 (one-tenth dilution of 8% solution). This was incubated at 37°C for 10 min and then precipitated before proceeding as described for HA modification. Segment V was cleaned using MERmaid (Stratech Scientific Ltd).
